We have examined the urinary excretion of stable immunoreactive eicosanoids in 23 female patients with systemic lupus erythematosus (SLE), 16 patients with chronic glomerular disease (CGD), and 20 healthy women. SLE patients had significantly higher urinary thromboxane B2 (TXB2) and prostaglandin (PG) E2 excretion and significantly lower 6-keto-PGFI. than did healthy women. In contrast, CGD patients only differed from controls for having reduced 6-keto-PGF1I excretion. The group of SLE patients with active renal lesions differed significantly from the group with inactive lesions for having a lower creatinine clearance and urinary 6-keto-PGFI. and higher urinary TXB2.
Introduction
Prostaglandin (PG)'I2 or prostacyclin and thromboxane (TX) A2 are labile oxygenated metabolites of arachidonate with contrasting effects on platelet function, vascular tone, and glomerular function (1, 2) . In humans, the corresponding stable hydration products, 6-keto-PGFia and TXB2, respectively, are synthesized by renal cortical microsomes (3) , represent the most abundant cyclooxygenase products of arachidonate in isolated glomeruli (4) , and can be measured in urine (5, 6) .
The glomerular synthesis of vasodilator PGI2 and vasoconstrictor TXA2 might theoretically mediate and/or be regulated by changes in glomerular hemodynamics associated with progressive glomerular sclerosis (7) , by virtue of their effects on glomerular capillary plasma flow rate (QA) and on glomerular ultrafiltration coefficient (Kf) (2, 8) . To the extent that the urinary excretion of 6-keto-PGFIa and TXB2 is primarily a reflection of the renal synthesis of the unstable parent compounds (9), we have recently suggested that patients with systemic lupus erythematosus (SLE) and active renal disease can be characterized as having enhanced renal synthesis of TXA2 (10) , while sharing with other forms of chronic glomerular disease a reduced glomerular synthesis of PG12 and PGI2-dependent renal function (1 1).
The aims of the present studies were: (a) to define the status of cyclooxygenated products of renal arachidonate metabolism in SLE patients as compared with healthy controls and patients with chronic glomerulonephritis; (b) to characterize the nature of enhanced urinary TXB2-like immunoreactivity detected in SLE patients; (c) to assess the renal vs. extrarenal sources of urinary TXB2 in SLE; (d) to correlate changes in eicosanoid excretion with SLE renal lesions; and (e) to explore the functional measurements of eicosanoid excretion and renal function, performed under basal conditions and following administration of a cyclooxygenase inhibitor.
Methods
A total of 59 female subjects were studied on several occasions. 23 SLE patients, aged 14-62 yr (mean±SD, 34±14), were studied at three different institutions during a 3-yr period. 20 healthy women, aged 23-40 yr (mean±SD, 29±5), without personal or family history suggestive of an autoimmune state, and 16 patients aged 19-67 yr (mean±SD, 41±17) with clinically and bioptically ascertained chronic glomerulonephritis, were studied as controls. The nature and purpose of the study was explained to each subject, and informed consent was obtained from all subjects who entered this study. SLE patients included in the present study met the following criteria: (a) diagnosis of SLE as defined by the American Rheumatism Association (12) ; and (b) histologic verification of lupus nephritis provided by percutaneous renal biopsy. All biopsies were examined by light and electron microscopy, and by immunoflourescence. The characteristics of the examined tissue were defined according to the World Health Organization classification (13) , as no glomerular changes (class I), mesangial (class II), focal proliferative (class III), diffuse proliferative (class IV), and membranous (class V) glomerulonephritis. Thirteen patients satisfied criteria for clinical and renal activity of SLE, i.e., active renal lesions and one or more of the following: arthralgia, pleuritis, pericarditis, vasculitis, myalgia, and cerebral involvement. Active renal disease was defined on the basis of histologic evidence ofactive nephritis (glomerular hypercellularity; foci of necrosis ofglomerular tufts; tubular, interstitial, and vascular changes) and either low serum C3 levels or the presence of serum antibodies to native DNA. 12 out of these 13 patients had diffuse proliferative and necrotizing glomerulonephritis (class IV B), while one had focal segmental and necrotizing glomerulonephritis (class III A). Class IV B lesions were also characterized by infiltration of mononuclear cells, and/or immune deposits in the tubular basement membrane, interstitial tissue, and peritubular capillaries. Glomerulosclerosis, intimal sclerosis of vessels, and interstitial fibrosis were considered inactive lesions. The histologic findings in the 10 patients with inactive renal lesions included minor glomerular abnormalities (1, class I B), mesangial proliferative (1, class II B), focal segmental (2, class III C), diffuse proliferative (3, class IV A), and diffuse membranous (3, class V A) glomerulonephritis. 7 ofthe 13 SLE patients with active renal lesions and 4 of the 10 patients with inactive lesions had mild to severe hypertension (diastolic blood pressure, 90-115 mmHg). The histologic diagnosis in the 16 patients with other forms of chronic glomerular disease included membranoproliferative glomerulonephritis, membranous glomerulonephritis, IgA nephropathy, mesangial IgM glomerulonephritis, Alport's disease, and renal amyloidosis. Four of these patients had mild to moderate hypertension. Three of the SLE patients with active renal lesions and two ofthe patients with chronic glomerular disease had the nephrotic syndrome. All patients were studied while hospitalized and kept on a controlled diet (sodium, 1.00 mmol/d; potassium, 80 mmol/d). None of the subjects was on cytotoxic drugs, nonsteroidal antiinflammatory drugs, or other drugs known to interfere with renal or platelet arachidonate metabolism, at the time of study.
Basal study. Each patient was studied at least on three consecutive occasions with biochemical and functional measurements. The renal synthesis of PGE2, PGF2., PG12, and TXA2 was investigated by measuring the urinary excretion ofPGE2, PGF2., 6-keto-PGFI., and TXB2, respectively, in 8-24-h urine collections, as previously described (6, 14, 15) . Simultaneous measurements of creatinine clearance were obtained on three consecutive days. Extrarenal TXB2 production was assessed by measurement of the urinary excretion of 2,3-dinor-TXB2 (16) and of plasma and serum concentrations of TXB2. Venous blood samples (5 ml) were drawn at 10 a.m., 2 h after a light breakfast, on the same days of urine collection. 2 ml of blood were promptly distributed into iced tubes containing EDTA (0.02 ml of a 5% solution per milliliter ofblood) and fenoprofen sodium salt (10 tg per milliliter of blood; Eli Lilly & Co., Indianapolis, IN), to prevent platelet TXA2 synthesis and release after sampling. All tubes were promptly centrifuged in a refrigerated centrifuge, and supernates were frozen for subsequent analysis. Platelet TXA2 production in response to endogenous thrombin was studied by letting triplicate l-ml aliquots of whole blood clot at 370C for 60 min, as previously described (17, 18) .
Ibuprofen study. Five healthy women, four SLE patients (three with inactive renal lesions and one with active renal lesions), and seven patients with chronic glomerular disease gave informed consent to participate in a study of the functional and biochemical effects of a nonselective cyclooxygenase inhibitor, i.e., ibuprofen (1,200 mg/d) given orally for 7 d (11). 24-h urine specimens and blood samples were obtained on the fourth, fifth, and sixth days ofdrug therapy for eicosanoid measurements and creatinine clearance determinations, and paraaminohippurate (PAH) clearance was measured on the seventh day, as described (11). PAH clearance was not determined in healthy women.
Analyses. Levels of serum and urinary creatinine were measured by the Jaffe chromogen reaction. The method of Bratton and Marshall was used to determine the levels of serum and urinary PAH. All clearance values were corrected for body-surface area. Urinary PGE2, PGF2., 6- keto-PGFIa, and TXB2 were measured by previously described radioimmunoassay (RIA) techniques (6, 14, 15) , after extraction and silicic acid column chromatography. Because of the instability of PGE2 in human urine, urine specimens were frozen immediately after collection and were kept at -20'C until extracted. Validation of urinary RIA measurements was obtained by several independent criteria, i.e., dilution and recovery studies; comparison among multiple antisera; characterization of the chromatographic pattern of distribution of the extracted PG-like and TX-like immunoreactivity on thin-layer chromatography (TLC); comparison with gas chromatography/mass spectrometry (GC/MS) determinations. These techniques are described in detail elsewhere (6, 14, 15) .
For comparison of urinary TXB2-like immunoreactivity with GC/MS determination, a 200-ml sample pooled from three consecutive urine collections obtained from a patient with active SLE was subjected to extraction and silicic acid column chromatography. The column eluate corresponding to TXB2 was then subjected to TLC. Silica gel corresponding to the TXB2 area, as determined by comparison with cochromatographed authentic TXB2, was scraped offand eluted with methanol. This was divided into two identical aliquots and evaporated to dryness. TXB2 concentrations were determined by RIA in our laboratory, and by GC/MS in the Burroughs Wellcome and Co. Research Laboratories (Beckenham, Kent, England) through the courtesy of Dr. John Salmon. The eluates obtained from a side lane of the same plate were subjected to the same procedure and used as a blank. For GC/MS analysis, the urine extract, the standard, and the blank were derivatized by reaction with freshly prepared diazomethane, methoxylamine hydrochloride, and finally bis-(trimethyl silyl)-trifluoroacetamide containing 1% trimethylchlorosilane. The derivatives were injected into a gas chromatograph (model 5730; Hewlett-Packard Co., Palo Alto, CA) combined with a mass spectrometer (VG Micromass 16 F; Hewlett-Packard Co). The gas chromatograph was fitted with a 1% OVl column operated at 240°C. Selected ion monitoring of mass to charge ratio (m/z) 301 was performed at 28 eV; the source current and temperature were 200 MA and 240°C, respectively. The urine extract, as well as the cochromatographed authentic TXB2, produced the largest ion at m/z 301 at the same retention time as the derivatized standard. No such ion was detected in the blank.
The (17, 18) . Unextracted samples were diluted in the standard diluent of the assay (0.02 M P04 buffer, pH 7.4) and assayed in a volume of 1.5 ml at a final dilution of 1: 15 (plasma) or 1:500-1:15,000 (serum). The least detectable concentration that could be measured with 95% confidence was 1 pg of TXB2 per ml of incubation mixture. Therefore, the detection limit of the assay was 15 or 500 pg/ml of plasma or serum, respectively. Results were analyzed using one-way analysis ofvariance, for multiple comparisons, and t test for single comparisons. Moreover, eicosanoid measurements were correlated with functional measurements by stepwise regression analysis and multiple linear regression. All values are reported as means± 1 SD. Statistical significance was defined as P < 0.05.
Results
The basal measurements of platelet and renal arachidonate metabolites obtained in the four groups of subjects are summarized in Table I . The intra-subject variability of urinary excretory rates ofthe four eicosanoids, measured on one to six occasions, ranged between 16 and 21%, and did not differ among the four groups of subjects. When compared with healthy women, both groups ofSLE patients had significantly higher urinary TXB2 and PGE2 excretion and significantly lower 6-keto-PGFIa. However, while all but one patient in each group had urinary TXB2> 2 SD of the normal mean, only six patients with active-renal lesions and two patients with inactive lesions had urinary PGE2> 2 SD of the normal mean. No statistically significant correlation was found between excretory rates ofthese eicosanoids in either group of SLE patients. In contrast, patients with chronic glomerular disease only differed from healthy women for having significantly reduced 6-keto-PGFIa excretion. The group of SLE patients with active renal lesions differed significantly from the group with inactive lesions for having a lower creatinine clearance (69±29 vs. 92±18 ml/min per 1.73 m2), a lower urinary 6-keto-PGFIa (2.0±1.0 vs. 3.4±0.4 ng/h) and higher urinary TXB2 (9.4±4.5 vs. 4.6±1.6). Such higher excretion ofTXB2 was associated with comparable platelet TXB2 production in whole blood (179±85 Table II .
To characterize the nature of this enhanced urinary TXB2-like immunoreactivity, 18 urinary samples from 12 SLE patients were analyzed for TXB2 by three different anti-TXB2 sera. Two of these, which showed a limited cross-reactivity (1.3 and 2.0%, respectively) with 2,3-dinor-TXB2 (18), gave almost identical results (r = 0.97, P < 0.001). A third anti-TXB2 serum, which had '50% cross-reactivity with 2,3-dinor-TXB2, gave twofold higher estimates of TXB2-like immunoreactivity, though these correlated with the former in a statistically significant fashion (r = 0.83 and 0.89, respectively; P < 0.01). When a pooled urinary extract from SLE patients was subjected to TLC, anti-TXB2 serum 3 revealed the presence of two distinct peaks of immunoreactivity, co-migrating with authentic TXB2 and 2,3-dinor-TXB2, respectively (Fig. 1) . In contrast, anti-TXB2 sera 1 and 2 detected a single peak of immunoreactivity co-migrating with authentic TXB2. The qualitative as well as the quantitative pattern of distribution of TXB2-like immunoreactivity in the region of authentic TXB2 was substantially identical with the three antisera (Fig. 1) . This finding strongly supports the identification of the urinary immunoreactive material as TXB2. Further evidence for this conclusion was obtained from GC/MS analysis. Thus, RIA detected 51 ng of TXB2 in the same region of the TLC plate where GC/MS measured 45 ng. To provide further evidence for the intrarenal vs. extrarenal source of enhanced urinary TXB2 detected in SLE patients, we have measured the urinary excretion of 2,3-dinor-TXB2, the major urinary metabolite ofinfused TXB2 in man (16), primarily reflecting systemic, i.e., extrarenal TXB2 production (9) . As shown in Table III , both groups ofSLE patients excreted amounts of 2,3-dinor-TXB2 comparable to that found in a group of agematched healthy women, despite markedly different excretory rates of TXB2. No statistically significant correlation was found between the two sets ofmeasurements in any ofthe three groups considered.
To assess the possible association of changes in vasoactive eicosanoid production with the basal status of renal function in SLE patients, urinary excretory rates of the four major cyclooxygenase products were correlated with the creatinine clearance rate (Ccr) and PAH clearance rate (Cp.H A significant inverse correlation was found between urinary TXB2 excretion and Cc, (y = 112.1-4.18x-, r = -0.64; n = 28; P < 0.005). A similar trend was noted for CPm, though the small number of patients examined (n = 8) precluded statistical significance (r = -0.478). Urinary TX% did not correlate with the degree of proteinuria.
In contrast, the urinary excretion of 6-keto-PGFIa showed a significant positive correlation with both Ccr (y = 45.1 + 14.2x-, r = 0.56; n = 28; P < 0.005) and CpAH (y = 75.5 + 238x, r = 0.70; n = 8; P < 0.05). When the ratio of urinary TXB2 to Evidence for a functional prevalence of vasodilator PGI2 over vasoconstrictor TXA2 is provided by the short-term effects of ibuprofen. Fig. 3 compares changes in urinary 6-keto-PGFia and TXB2 and in Cc, and CPAH, associated with l-wk dosing with this nonselective cyclooxygenase inhibitor in four SLE patients and five healthy women. In SLE patients, pharmacologic inhibition of renal cyclooxygenase activity was associated with a significant (P < 0.01) reduction in urinary 6-keto-PGF1, by 77% and in TXB2 by 67%, and in both Ccr and CPAH by 26% and 34%, respectively. In healthy women, a similar reduction ofurinary 6-keto-PGFI, and TXB2 by 73% and 66%, respectively, was not associated with any detectable change in Ccr. (Table V) . Thus, the average decrease in both clearances was -50% lower in SLE patients than in patients with chronic glomerular disease, when fractioned by the reduction in urinary 6-keto-PGFIa excretion. Similar results were obtained when individual changes in Cc, and CPAH were fractioned by the reduction in urinary PGE2 excretion (Table VI) . Thus, simultaneous suppression by ibuprofen of enhanced renal TXA2 production might possibly account for such pattern, by attenuating the consequences of reduced vasodilatory PGs. Such interpretation is supported by the finding that the actual reduction in Ccr measured in the 11 patients treated with ibuprofen (-22 .4+7.4 ml/min per 1.73 m2) did not differ significantly from the expected value (-24.1 ± 15.6 ml/min per 1.73 m2) calculated on the basis of theoretical changes in Cc, associated with the observed changes in U-6-keto-PGF1, and U-TXB2 excretion.
Discussion
Several experimental models of nonimmune as well as immunemediated renal damage are associated with quantitative and qualitative alterations of renal arachidonate metabolism (20) . Thus, a ureteral obstruction model of hydronephrosis (21) , renal venous occlusion (22) , and glycerol-induced acute renal failure in rabbits (23) all share a marked enhancement of renal PGsynthesis and the induction of TXA2 production. Indirect pharmacologic evidence, largely derived from the use of selective TX-synthase inhibitors, suggests a pathophysiologic role for such vasoactive eicosanoids in mediating changes in renal vascular resistance and regional blood flow (20) . Similarly, in antiglomerular basement membrane antibody-induced glomerulonephritis in the rat, there is enhanced synthesis of TXA2 and PGs in the glomerulus, that mediate changes in renal hemodynamics (24). Because both vasodilator and vasoconstrictor arachidonate derivatives are synthesized by human glomeruli (3, 4) , and their stable hydration products can be measured in urine (5, 6), we initiated a search for alterations in their relative production in human models of glomerular disease. Urinary TXB2/ 6-keto-PGFla We report increased urinary excretion ofTXB2 and decreased urinary excretion of 6-keto-PGFIa in female patients with SLE as the most prominent and specific alteration of renal arachidonate metabolism and provide evidence for its functional significance. The identification of the immunoreactive material present in the urine of SLE patients as TXB2 was obtained by several independent criteria: (a) its identical immunochemical behavior with authentic TXB2 upon dilution; (b) its identical chromatographic behavior with authentic TXB2 upon TLC separation; (c) its detection by three different anti-TXB2 sera; and (d) its detection by GC/MS. It is generally accepted that the urinary excretion of unmetabolized PGE2 and PGF2a largely reflects the renal synthesis of these compounds in healthy women (25), as primary PGs are not detectable in the systemic circulation and are currently viewed as locally active modulators. Despite early claims to the contrary, this seems to apply also to PGI2 and TXA2 (9) . However, inasmuch as a small fraction ofexogenously infused TXB2 can be recovered unchanged in urine (16), the possible contribution ofextrarenal sources ofTXA2 production should be considered when claiming an intrarenal origin of urinary TXB2 in disease states. Platelets represent a major source of TXB2 in the human body, inasmuch as the urinary excretion of its major metabolite 2,3-dinor-TXB2 is largely suppressed by daily lowdose aspirin administration (19) , which does not affect renal cyclooxygenase activity (18) . The finding of(a) slightly reduced TXB2 production in whole blood, (b) undetectable TXB2 in peripheral venous plasma, and (c) urinary 2,3-dinor-TXB2 excretion in the normal range, makes it unlikely that extrarenal platelet activation can account for enhanced urinary TXB2 excretion in SLE patients. Intrarenal platelet activation (26) can also be excluded on the basis of our earlier observation (15) The possibility that filtered protein traps TXB2 in the kidney and hence enhances urinary TXB2 excretion is unlikely in view of the absence of any statistically significant correlation between protein and TXB2 excretion in SLE patients, and of the normal TXB2 excretion in two patients with chronic glomerulonephritis (type I membranoproliferative and mesangial IgM glomerulonephritis, respectively) who had the nephrotic syndrome.
-Finally, one might consider the occurrence of an IgM autoantibody directed against lipomodulin (a phospholipase A2 inhibitory protein), described by Hirata et al. (29) in sera of SLE patients and New Zealand Black X New Zealand White F1 mice. The antilipomodulin antibody potentiates the stimulatory activity of bradykinin on the release of arachidonate from human fibroblasts (29), and might similarly affect intrarenal TXA2-producing cells. Interestingly, in New Zealand Black X New Zealand White F. mice there is also increased renal production of TXB2 but not of PGE2 (V. E. Kelley, personal communication).
The finding that both groups of SLE patients had significantly lower 6-keto-PGFIa excretion than did healthy women is consistent with our recent observation that the vast majority of patients with chronic glomerular disease display such biochemical abnormality, regardless of the nature of the glomerular involvement (1 1). At least two distinct mechanisms may account for a reduction in the glomerular synthesis of PGI2, i.e., (a) inhibition of PGI2-synthase by hydroperoxy-derivatives of arachidonate (30) , or (b) feedback regulation of PGI2 synthesis by the hemodynamic changes associated with progressive glomerular sclerosis (7) . Although no specific recognition pattern can be ascribed to either enhanced urinary TXB2 or reduced urinary 6-keto-PGFI. excretion alone, the simultaneous occurrence of the two in SLE patients had a high discriminating power in our limited series.
The functional significance of biochemical changes detected in SLE patients is borne out by significant correlations with Ccr and CPAH in the basal state and by changes of these parameters associated with cyclooxygenase inhibition. As for the former, these are consistent with the known influences of TXA2 and PGI2 on glomerular hemodynamics and on the contractility of glomerular mesangial cells (2, 8) . Within the limits of the assumption that changes in the urinary excretion of TXB2 and 6-keto-PGFia reflect changes in renal TXA2 and PGI2 synthetic rates (31), respectively, the vasodilatory influence of the latter seems to outweigh the vasoconstrictor and contractile actions ofthe former. Evidence supporting this conclusion derives from the following observations in SLE patients: (a) the slope of the regression line of urinary 6-keto-PGFIa over Ccr was approximately fourfold greater than the corresponding value for the regression ofurinary TXB2; (b) administration ofa nonselective cyclooxygenase inhibitor, suppressing renal TXA2 and PGI2 synthesis to a similar extent, significantly reduced Ccr and CpAH .
In the present study, there is a linear correlation between urinary 6-keto-PGFIa excretion and Ccr when data from all the groups are considered (Fig. 4) On the other hand, our results do not provide evidence for enhanced renal synthesis of vasodilator PGE2 as a consistent hallmark of the cyclooxygenase-dependence of renal function in SLE, as suggested by the early observations of Kimberly et al. (33) . However, it should be pointed out that enhanced glomerular PGE2 production may not be reflected by urinary PGE2 excretion, which largely reflects a medullary origin. Thus, decrements in renal function after ibuprofen may well depend upon reductions in the cortical synthesis of both PGI2 and PGE2.
More direct evidence for the functional significance of renal TXA2 synthesis in SLE would require the use of a selective TXsynthase inhibitor or a TXA2-receptor antagonist. However, three currently available imidazole-analogue TX-synthase inhibitors, i.e., dazoxiben (34), OKY-046 (35) , and UK-38,485 (36) only marginally (<40%) reduced urinary TXB2 excretion when given to healthy subjects at doses fully suppressing platelet TXB2 production. Similarly, differential inhibition of platelet vs. glomerular TX-synthase detected in vitro (34) was also observed ex vivo in rats with nephrotoxic serum nephritis (24). Whether a 7/02 *s Tables I and  IV. tissue-selective TX-synthase inhibitor or a TXA2-receptor antagonist may indeed improve renal function in SLE patients remains to be determined.
We conclude that, in SLE patients (a) a complex alteration in renal arachidonate metabolism exists, the most consistent and specific features of which are reflected by enhanced urinary excretion of TXB2 and decreased urinary excretion of 6-keto-PGF1,; (b) the severity of such biochemical alterations correlates with the activity of renal lesions and with deteriorating renal function; (c) PGI2 is a determinant ofglomerular hemodynamics and its suppression by cyclooxygenase inhibitors accounts for the reduction in renal function associated with these drugs; (d) the simultaneous suppression of intrarenal TXA2 synthesis partially attenuates the functional consequences of cyclooxygenase inhibition, as compared with other forms of chronic glomerular disease with normal TXB2 excretion; and (e) the long-term consequences of selective vs. nonselective pharmacologic modulation of renal arachidonate metabolism remain to be determined. Urinary 6-keto-PGF10 (ng/h)
